{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Survival Status: Alive"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Survival Status: Deceased (relapse)"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"title":"Survival Status: Deceased (fungal infection)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"If CCR5delta32 homozygous donors are successfully found and used for one or more HIV-positive subjects, a descriptive analysis of baseline characteristics and outcomes for those HIV-positive subjects will be conducted, including the viral load detected over time obtained from collected samples.","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Four subjects with HIV-positive, no statistical analysis for this outcome measure was completed due to limited HIV-positive rate. Descriptive analysis provided.","reportingStatus":"POSTED","timeFrame":"365 days post transplant","title":"Subgroup Analysis of HIV-positive Subjects","type":"SECONDARY","unitOfMeasure":"Participants"}